Newer oral anticoagulants and antiplatelet therapies have become an integral part of thromboembolic disease management. However, only a few studies have established the safety profile of these medications. A recent clinical study published in the JAMA Ophthalmology reported the decreased risk of intraocular haemorrhage associated with novel direct thrombin inhibitors and direct factor Xa inhibitors. Nowadays, new antithrombotic medications are widely prescribed for the management of coronary artery disease and atrial fibrillation.
With regard to this, the ocular safety profile of these medications must also be understood while prescribing these drugs. Study details The retrospective cohort study compared all patients on dabigatran etexilate or rivaroxaban therapy with patients on warfarin sodium therapy. Also, patients who were newly prescribed with prasugrel hydrochloride were compared…
